Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brief-ACT + Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
NCT07570368Not yet recruiting
- Sponsor
- Universitas Airlangga
- Start
- Apr 2026
- Primary completion
- Jan 2027
01
Overview
Randomised trial (2 arms), sponsored by Universitas Airlangga. Primary endpoint: Clinical response according to RECIST version 1.1 at 9 weeks. Planned start Apr 2026; status: not yet recruiting.
Beyond the preview
Go deeper on NCT07570368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570368.